Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.

Why Wall Street loves Lilly. So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will ...

Parkland School Board members expressed deep skepticism about a proposed tax break for Eli Lilly, using their Tuesday ...

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

Following the US Food and Drug Administration approval of Foundayo on April 1 for chronic weight management, Eli Lilly is ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026.

By Siddhi Mahatole April 20 (Reuters) - U.S. drugmaker Eli Lilly will buy privately held biotech firm Kelonia Therapeutics ...

On April 15, 2026, Eli Lilly and Company (NYSE:LLY) reported topline results from the Phase 3 ACHIEVE-4 trial evaluating ...

Eli Lilly (NYSE: LLY) is reportedly in talks to acquire cancer biotech Kelonia Therapeutics in a deal that could be worth ...

The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly’s expansion into cancer treatments.

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...